VK2735, obesity and Viking Therapeutics
Viking Therapeutics VKTX announced that it has started the phase II VENTURE-Oral Dosing study to evaluate the safety and ...
Seeking Alpha analyst Terry Chrisomalis regards Viking Therapeutics as the most attractive M&A candidate in 2025, bolstered ...
Some of the best possible returns for investors come by not going after megacaps, but instead pursuing stocks that have more ...
Viking Therapeutics (VKTX) announced the initiation of a Phase 2 clinical trial of the oral tablet formulation of VK2735, the company’s dual ...
COO Marianna Mancini sold 54,215 shares of the firm’s stock in a transaction dated Monday, January 6th. The stock was sold at ...
Viking Therapeutics Inc’s profitability metrics reveal strong financial health. The company currently boasts a gross margin of -16.62%. The profit margin, also known as the revenue ratio or gross ...
Viking Therapeutics ( VKTX -2.05%) didn't exactly capture investors' hearts in the final month of 2024. The biotech company's ...
JPMorgan highlights valuation resets for Viking and Structure Therapeutics, citing opportunities in T2D/obesity and competitive clinical data insights.
JPMorgan keeps an Overweight rating and $80 price target on Viking Therapeutics (VKTX) after the company announced that it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback